Olmesartan medoxomil

This classification denotes an angiotensin ii receptor antagonist with the molecular formula C29H30N6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6M97XTV3HD, chemically known as 1h-imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2-(1h-tetrazol-5-yl) (1,1-biphenyl)-4-yl)methyl)- but more generally known as olmesartan, which bears US NIH Compound Identifier 158781. European Medicines Agency schedules Olmesartan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20707. The term OLMESARTAN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 13 No. 3, 1999, List 42). World Health Organization schedules olmesartan in its Anatomical Therapeutic Chemical (ATC) Classification. OLMESARTAN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule olmesartan medoxomil under HS 29349990 and SITC 51579. As of Q4 2014, OLMESARTAN MEDOXOMIL remains US FDA's Preferred Term for this commodity. Olmesartan medoxomil bears US NLM identifiers UMLS ID C0386393 and NCI Concept Code C47640. SMILES: CCCC1NC(C(N1CC2CCC(CC2)C3CCCCC3C4[NH]NNN4)C(=O)OCC5C(OC(=O)O5)C)C(C)(C)O.